Aleksey Krylov is a strategic Chief Financial Officer to life sciences and medical technology companies with a background in venture investing and M&A. With a track record of 70+ completed fundraising and M&A transactions, he blends deal-making and operating CFO skills to manage financial, investor relations and administrative functions of life sciences organizations.
Most recently he served as a Chief Financial Officer of CytoImmune Therapeutics, a cell immunotherapy company, where he raised more than $100m in funding, oversaw growth from three to 60+ employees and helped manage the buildout of a commercial scale cell and biologics manufacturing facility in Puerto Rico.
Previously, he served as a Chief Financial Officer of DIH International, Ltd., a Swiss-Chinese medical equipment manufacturer with $80m in sales and 400 employees globally, and drove the company’s preparedness for NASDAQ IPO. Prior to that, he was a Chief Financial Officer of SELLAS Life Sciences, Inc. (NASDAQ: SLS, peak market cap ~$170m), an oncology immuno-therapeutics company. At SELLAS he led the reverse merger of private SELLAS into a publicly listed target and raised $10.7 million in financing.
Prior to becoming CFO, for 12 years Mr. Krylov was a family office investment professional with a focus on M&A, capital raising, private equity investing and restructuring. His industries of interest included life sciences, medical technologies, healthcare IT and consumer products, among others. His track record includes principal and control investments of $500m+ across dozens of transactions.
Krylov began his career with SG Cowen’s equity capital markets group as an investment banker. Mr. Krylov holds an M.B.A. from Columbia Business School and a B.S. in Business Administration from Babson College.